Connect Conference & Show Floor Educational Sessions

View, browse and sort the list of Connect Conference sessions and show floor programming by pass type, track, and format. Please note, all Connect Conference delegates have access to InformEx Connect and CPhI Connect programming. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

To learn more about the Connect Conference program, click here.

All SessionsSpeakersMy Schedule
View Sessions As:
  • Innovative Breakthrough Technologies for Drug Targets and Emerging Pathways (Powered by American Chemical Society)

    • Matthew Shoulders Ph.D.  |  Whitehead Career Development Assistant Professor, Department of Chemistry, Massachusetts Institute of Technology
    • Peter D. Senter Ph.D.  |  Vice President, Chemistry and Senior Distinguished Fellow, Seattle Genetics
    Location:  113A
    Track: Drug Development
    Pass Type: Connect Delegate, VIP Attendee - Get your pass now!
    Vault Recording: TBD

    Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically Approved Drug
    Peter Senter, Vice President for Chemistry, Seattle Genetics

    Monoclonal antibodies (mAbs) have played a major role in cancer medicine, with active drugs such as trastuzumab (Herceptin), cetuximab (Erbitux), bevacizumab (Avastin) and rituximab (Rituxan) in a wide range of therapeutic applications. The mechanisms of these agents involve such activities as direct signaling, interactions with Fcg receptors on effector cells, and complement fixation. Several approaches have been explored to improve antibody-based therapies for cancer treatment by optimizing such activities and by conscripting their selectivity profiles for the delivery of high potency cytotoxic drugs. The field has advanced significantly in the past few years, with the approval of Adcetris (brentuximab vedotin) for the treatment of relapsed Hodgkin and anaplastic large cell lymphomas. The drug is comprised of a potent antimitotic agent, monomethyl auristatin E (MMAE), conjugated to an anti-CD30 mAb through a lysosomally cleavable dipeptide linker. This presentation will describe the discovery and development of Adcetris, and will overview advancements in the field of ADCs for cancer therapy.

    Multi-Dimensional Chemical Control of CRISPR-Cas9
    Matthew Shoulders Ph.D., Whitehead Career Development Assistant Professor, Department of Chemistry, Massachusetts Institute of Technology

    Cas9, an RNA-guided DNA endonuclease, has enabled facile and efficient induction of genomic alterations and their super-Mendelian self-propagation via gene drives. Catalytically inactive Cas9 can be fused to a wide range of effectors, including fluorescent proteins for genome imaging, DNA or histone modifying enzymes for epigenome editing, and transcription regulating domains for controlling endogenous gene expression. Yet, a critical need exists for methods to precisely and temporally control Cas9 activities across multiple dimensions, including dose and time. Finely-tuned control of Cas9 levels is necessary, as high Cas9 activity result in elevated off-target DNA cleavage and chromosomal translocations. Rapid activity termination after a desired genomic modification is also essential, but currently absent. Moreover, the addition of rapid, reversible, dose, temporal, and orthogonal controls to other CRISPR technologies (e.g., transcription activation/repression) can dramatically enhance their capabilities.

    We developed a CRISPR-Cas9 system with dose, temporal, and orthogonal control of Cas9-mediated activities (Nature Chem Biol 2017). Using this system, we have demonstrated dose-control of Cas9 activity and specificity, dose- and orthogonally controlled transcription of multiple endogenous genes, and tight temporal control of Cas9 activity. We envision that our chemical control approaches will find widespread use in biomedical and defense research. Our group is focused on applying methods like these to probe and modulate proteostasis in health and disease. Select applications of chemical biology methods to manipulate the proteostasis network will also be discussed.